Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Clin Exp Dermatol ; 48(4): 339-344, 2023 Mar 22.
Artigo em Inglês | MEDLINE | ID: mdl-36763742

RESUMO

BACKGROUND: Patch testing is an important investigation when dermatitis is unresponsive to, or worsened by, topical corticosteroid treatment. There is a balance to be struck between testing too many allergens, which is expensive, time consuming and risks causing sensitization, and testing too few, which risks missing the diagnosis. The current British Society for Cutaneous Allergy (BSCA) corticosteroid series comprises eight allergens and was last updated in February 2007. AIM: To review and update the BSCA corticosteroid series. METHODS: We retrospectively analysed data from 16 patch test centres in the UK and Ireland for all patients who were patch tested to a corticosteroid series between August 2017 and July 2019. We recorded the allergens tested, the number and percentage tested to a corticosteroid series and the number of positive results for each allergen. We identified the allergens that test positive in ≥ 0.1% of selectively tested patients. RESULTS: Overall, 3531 patients were tested to a corticosteroid series in the 16 centres. The number of allergens tested ranged from 7 to 18 (mean 10). The proportion of patch test patients who were tested to a corticosteroid series ranged from 1% to 99%. Six allergens in the 2017 BSCA series tested positive in ≥ 0.1% of patients. Nine allergens not in the BSCA corticosteroid series tested positive in ≥ 0.1% of patients. CONCLUSION: This audit demonstrates the importance of regular review of recommended series and the significant variations in practice. The new BSCA corticosteroid series that we recommend contains 13 haptens, with the addition of the patient's own steroid creams as appropriate.


Assuntos
Dermatite Alérgica de Contato , Dermatite Atópica , Humanos , Corticosteroides , Alérgenos , Dermatite Alérgica de Contato/diagnóstico , Dermatite Alérgica de Contato/etiologia , Dermatite Atópica/complicações , Testes do Emplastro , Estudos Retrospectivos
2.
Clin Exp Dermatol ; 47(8): 1583-1584, 2022 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-35436008

RESUMO

We report a patient with carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS), who developed painful dysphagia in the follow-up period. Gastrointestinal, including oesophageal, complications are rarely reported following DRESS, and we wish to highlight this possibly under-reported phenomenon.


Assuntos
Síndrome de Hipersensibilidade a Medicamentos , Eosinofilia , Anticonvulsivantes/efeitos adversos , Carbamazepina/efeitos adversos , Síndrome de Hipersensibilidade a Medicamentos/diagnóstico , Eosinofilia/tratamento farmacológico , Esôfago , Humanos
3.
Contact Dermatitis ; 85(6): 693-697, 2021 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-34418105

RESUMO

BACKGROUND: How many patients should we be patch testing? A previous study suggested that the minimum proportion of a population to be patch tested for allergic contact dermatitis was 1:700 annually. OBJECTIVES: To evaluate if the current minimum rate for patch testing has changed over the 20 years since the previous study in order to maximize the value. METHODS: In cooperation with the British Society for Cutaneous Allergy, a proforma for collation of retrospective data between January 2015 and December 2017 was sent to patch-test centers in the United Kingdom (UK) and the Republic of Ireland (ROI). The number of positive tests was analyzed against the proportion of population tested to see what proportion of the population would yield the greatest number of positive results. RESULTS: Responses from 11 centers showed that the minimum number needed to patch test had increased to 1:550 per head of population per year using the current criteria. CONCLUSIONS: In agreement with previous studies, we should be patch testing more people than we are. We could reduce the threshold for referral of patients we patch test to derive the most benefit from this investigation.


Assuntos
Dermatite Alérgica de Contato/diagnóstico , Testes do Emplastro/estatística & dados numéricos , Encaminhamento e Consulta , Dermatite Alérgica de Contato/epidemiologia , Utilização de Instalações e Serviços , Humanos , Irlanda/epidemiologia , Estudos Retrospectivos , Reino Unido/epidemiologia
4.
J Photochem Photobiol B ; 101(2): 169-73, 2010 Nov 03.
Artigo em Inglês | MEDLINE | ID: mdl-20452781

RESUMO

Oral ingestion of green tea is a potent dietary source of antioxidant polyphenols. These compounds are of interest as they may be able to provide additional protection to the body to help prevent the deleterious effects of ultraviolet A and visible radiation (UVA/VIS) produced indirectly via reactive oxygen species (ROS) in sunlight exposed skin. A small clinical study was conducted in ten healthy adult volunteers. Samples of whole blood were obtained from each before and 30, 60 and 90 min following ingestion of three breakfast cups of green tea (540 ml in total) prepared in a standardised manner. Peripheral leucocytes were isolated from each blood sample and exposed to increasing periods of UVA/VIS irradiation in the laboratory (0, 9, 12 or 18 min). Alkaline single cell gel electrophoresis (the comet assay) was then conducted to determine the level of DNA damage in each sample from each individual. The findings support those of our previous pilot study and indicate that drinking green tea did significantly reduce the genotoxic effects observed in peripheral blood cells 60 min following ingestion when artificially exposed to 12 min of UVA/VIS irradiation in the laboratory. It is postulated that this protection is afforded by the polyphenol compounds (known to be contained within green tea) via scavenging or quenching of the damaging ROS induced by this form of light exposure. Further investigation should consider whether this dietary-induced protection could be extended to cells of the skin.


Assuntos
Antioxidantes/farmacologia , Dano ao DNA/efeitos dos fármacos , Luz/efeitos adversos , Chá , Raios Ultravioleta/efeitos adversos , Adulto , Ensaio Cometa , Feminino , Humanos , Masculino , Espécies Reativas de Oxigênio/metabolismo , Chá/química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA